Afuco™ Anti-TNFRSF9 ADCC Therapeutic Antibody (Urelumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to 4-1BB. Urelumab (ue rel' ue mab; also known as BMS-663513 and anti-4-1BB antibody) is a fully human IgG4 monoclonal antibody for the treatment of cancer and solid tumors.
Urelumab targets the CD137 receptor. It specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells.
Urelumab targets the CD137 receptor. It specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-179 |
| Pricing | Inquiry |
| Host | Human |
| Target | TNFRSF9 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | ELISA, FC, IP, FuncS, IF, Neut |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |